ライフサイエンスコーパス: intraocular pressure

1 previously analyzed clinical measures (i.e., intraocular pressure).

2 ighlight the importance of proper control of intraocular pressure.

3 t to the cornea and lens, and by maintaining intraocular pressure.

4 he plasma into the aqueous humor, increasing intraocular pressure.

5 indness that occurs without grossly abnormal intraocular pressure.

6 dritic compartment of RGCs subjected to high intraocular pressure.

7 plete data on health status and 366 (87%) on intraocular pressure.

8 tral corneal thickness, axial eye length, or intraocular pressure.

9 significant change in mean visual acuity or intraocular pressure.

10 duce both pharmacologically raised and basal intraocular pressure.

11 tion of steroid administration, and elevated intraocular pressure.

12 eal angle exhibited a significantly elevated intraocular pressure.

13 uveitic glaucoma require surgery to control intraocular pressure.

14 ar meshwork cells, resulting in elevation of intraocular pressure.

15 The most common adverse event was increased intraocular pressure.

16 without post-operative increase in the mean intraocular pressure.

17 eous humor outflow and maintenance of normal intraocular pressure.

18 ng, visual field testing, and measurement of intraocular pressure.

19 m a severely hypomorphic canal with elevated intraocular pressure.

20 s optic neuropathy despite a well-controlled intraocular pressure.

21 and visual loss, death of participants, and intraocular pressure.

22 are associated with a sustained increase in intraocular pressure.

23 igher (95% CI 0.015-0.088, p=0.005) and mean intraocular pressure (16.6 [SD 3.5] mm Hg) 1.18 mm Hg lo

24 excavation (20%), relatively low (<10 mmHg) intraocular pressure (22%), and optic nerve hypoplasia (

25 d newly diagnosed primary angle closure with intraocular pressure 30 mm Hg or greater or primary angl

26 The mean highest intraocular pressure (32.2+/-9.7 vs. 17.6+/-3.6 mmHg; P

27 al decompensation, lens opacities and raised intraocular pressures 4 years following bilateral NewCol

28 sistance of the aqueous drainage tissues and intraocular pressure, a key pathogenic factor of glaucom

29 tcomes included changes in visual acuity and intraocular pressure, ability to taper concomitant immun

30 Control of intraocular pressure after implantation of a glaucoma dr

31 ree eyes required paracentesis to reduce the intraocular pressure after injection and to restore cent

32 new candidate gene, Cacna2d1, that modulates intraocular pressure and a promising therapeutic, pregab

33 Also close monitoring of the intraocular pressure and assessment of eventual bleb mor

34 r hypotensive agents is important to control intraocular pressure and hence to prevent progressive gl

35 uate the etiopathologic relationship between intraocular pressure and ocular biometric parameters and

36 The aim of this study was to assess the intraocular pressure and ocular biometric parameters in

37 ations of the metabolic syndrome (MetS) with intraocular pressure and primary open angle glaucoma (OA

38 ous, oral and topical--with normalization of intraocular pressure and resolution of choroidal folds a

39 k is potentially an important determinant of intraocular pressure and success of trabecular bypass gl

40 ght into a potential contributor to elevated intraocular pressure and thus to probability of glaucoma

41 cluded measurement of visual acuity (VA) and intraocular pressure, and a detailed anterior and poster

42 al acuity, perimetry, slit-lamp examination, intraocular pressure, and fundus photography.

43 netic and molecular mechanisms that regulate intraocular pressure, and identifies a new candidate gen

44 dpoints were patient-reported health status, intraocular pressure, and incremental cost-effectiveness

45 s, larger vertical cup-to-disc ratio, higher intraocular pressure, and self-reported black race were

46 outcomes included changes in visual acuity, intraocular pressure, and trends in scleral grading.

47 Clinical data, including systemic disorders, intraocular pressure, and visual outcomes were recorded.

48 microbeads was made in mouse eyes to elevate intraocular pressure as a model of experimental glaucoma

49 Elevated intraocular pressure as the result of abnormal resistanc

50 Torsional power was set at 60% and intraocular pressure at 50 mm Hg.

51 coma surgery and use of medications to lower intraocular pressure at the time of surgery vs 22% with

52 records of 22 eyes of 20 patients with high intraocular pressure at various stages of the MOOKP proc

53 ot a statistically significant difference in intraocular pressure between the migraine patients durin

54 l examination (best-corrected visual acuity, intraocular pressure, biomicroscopic examination of the

55 ral or clear superior wound, does not affect intraocular pressure, bleb morphology or function after

56 ured included GCC thickness, autorefraction, intraocular pressure, blood pressure, body mass index, a

57 m to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-co

58 otential ocular side effects (e.g., elevated intraocular pressure, cataracts).

59 formed after one year of follow-up regarding Intraocular pressure changes, bleb morphology score usin

60 5 days led to a much more efficient drop of intraocular pressure compared to the standard drug dorzo

61 in-the-bag intraocular lens implantation on intraocular pressure control and the bleb morphology in

62 uccessfully placed in both eyes and adequate intraocular pressure control was achieved for 4 months.

63 Secondary outcomes included intraocular pressure control, worsening of visual acuity

64 tube in the posterior chamber with adequate intraocular pressure control.

65 a, photophobia, and blepharospasm; increased intraocular pressure; corneal clouding at birth; and bup

66 This sustained elevated intraocular pressure could lead to higher rates of glauc

67 those seen in single oil tamponade (elevated intraocular pressure, cystoid macular oedema (CMO), cata

68 lowing pilocarpine administration, mean (SD) intraocular pressure decreased from 14.3 (1.3) to 13.7 (

69 se the common causal risk factor of elevated intraocular pressure, delay, but cannot prevent, RGC dea

70 unction (91.2% to 96.1%, P < .02) and target intraocular pressure determination (73.7% to 83.2%, P <

71 with other clinical measures (visual acuity, intraocular pressure, Disc Damage Likelihood Scale, and

72 ive uveitis (r = -0.41; P < 0.0001), maximum intraocular pressure during the course of disease (r = -

73 e the most vulnerable to transient transient intraocular pressure elevation as measured by rates of c

74 Intraocular pressure elevation greater than 10 mm Hg fro

75 Intraocular pressure elevation measures occurred more fr

76 for the first time, the effects of transient intraocular pressure elevation on the structure and func

77 2 %) patients in early postoperative period, intraocular pressure elevation was detected in 12 (33.3

78 Intraocular pressure elevation was not observed in exper

79 Intraocular pressure elevation was the second most commo

80 ur early, within 14 d after acute, transient intraocular pressure elevation, have not been previously

81 common cause for postoperative elevation of intraocular pressure, especially in children.

82 rvals or as needed, including visual acuity, intraocular pressure, external eye examination, and fund

83 At the last visit, the mean intraocular pressure for the temporal group was 17.55 +/

84 Outcome measures included reduction in intraocular pressure from baseline, survival analysis, a

85 Fifteen treatment-naive patients had intraocular pressure >/=25 mm Hg; none required laser or

86 sives (normal disc, normal visual field, and intraocular pressure >22 mmHg).

87 Postoperative elevation in intraocular pressure (>/=30 mmHg) was documented in 3 ey

88 loaters that may present with an increase in intraocular pressure immediately, or many months after t

89 leation due to phthisis bulbi), and elevated intraocular pressure in 3 patients (2 eyes in the PPV gr

90 the trabecular AH outflow pathway increases intraocular pressure in a Rho kinase-dependent manner.

91 oprietary hypotensive agent, DE-117, reduced intraocular pressure in normotensive rabbits significant

92 l (MIGS) devices are one option for lowering intraocular pressure in patients with glaucoma.

93 mycin may be similarly effective in lowering intraocular pressure in primary open-angle glaucoma.

94 evented or reversed pharmacologically raised intraocular pressure in rabbits.

95 Elevated intraocular pressure in the RhoAV14-expressing rats was

96 Her intraocular pressure in the right eye was raised at 55 m

97 y improvement without clinically significant intraocular pressure increases.

98 mptomatic floaters presenting with very high intraocular pressure (IOP >40 mm Hg) were selected.

99 beculectomy surgery, with failure defined as intraocular pressure (IOP) > 21 mmHg, </= 5 mmHg or not

100 laucoma or ocular hypertension and with mean intraocular pressure (IOP) >/=21 mm Hg and <32 mm Hg whi

101 er Grade 3 and 4) and uncontrolled medicated intraocular pressure (IOP) >21 mm Hg at baseline and can

102 the need for repeat surgery or uncontrolled intraocular pressure (IOP) >22 mm Hg, despite topical/sy

103 Success was defined with 3 criteria: (1) intraocular pressure (IOP) </= 21 mm Hg and IOP reductio

104 levels of success criteria were defined: (A) intraocular pressure (IOP) </=18 mm Hg and IOP reduction

105 ords and classified into subtypes defined by intraocular pressure (IOP) (>/=22 or <22 mm Hg) or by vi

106 jects had POAG with mean diurnal unmedicated intraocular pressure (IOP) 21-33 mmHg and were undergoin

107 ersible vision loss worldwide, with elevated intraocular pressure (IOP) a major risk factor.

108 To examine risk factors for low intraocular pressure (IOP) after trabeculectomy and to d

109 Intraocular pressure (IOP) and cataract formation were d

110 current study was focused on the effects of intraocular pressure (IOP) and choroidal circulation on

111 e-dependent effect on the difference between intraocular pressure (IOP) and intracranial pressure (IC

112 To compare intraocular pressure (IOP) and IOP-lowering treatment re

113 High intraocular pressure (IOP) and large vertical cup-to-dis

114 his therapy may cause sustained elevation of intraocular pressure (IOP) and may potentially increase

115 sty (SLT) has been demonstrated to lower the intraocular pressure (IOP) and medication use in NTG.

116 Intraocular pressure (IOP) and optic nerve head characte

117 To determine the incidence of elevated intraocular pressure (IOP) and secondary glaucoma in her

118 m Aluminium Garnet) laser capsulotomy on the intraocular pressure (IOP) and the trabeculectomy bleb i

119 f glaucoma treatment is to lower and control intraocular pressure (IOP) and thereby prevent functiona

120 tio greater than or equal to 0.6 with normal intraocular pressure (IOP) and visual fields.

121 r-directional ocular fluid current driven by intraocular pressure (IOP) as well as unfavorable drug d

122 The outcome of interest was intraocular pressure (IOP) at 3 months.

123 OBSERVATION: Intraocular pressure (IOP) at the end of the surgery, im

124 nstrate that DBA/2J.Wld(s) mice develop high intraocular pressure (IOP) but are protected from retina

125 s dorzolamide (1) and brinzolamide (2) lower intraocular pressure (IOP) by inhibiting the carbonic an

126 Intraocular pressure (IOP) decreased from 23.2 mmHg (SD

127 illimeter of mercury increase in the average intraocular pressure (IOP) during follow-up, the ONH and

128 mechanism to effectively treat glaucomatous intraocular pressure (IOP) dysregulation.

129 k (TM) is associated with TM dysfunction and intraocular pressure (IOP) elevation in glaucoma.

130 f the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVT

131 Intraocular pressure (IOP) elevation was relatively rapi

132 Upon intraocular pressure (IOP) elevation, CSS appeared hyper

133 The baseline intraocular pressure (IOP) for SLT 1 = 20.3+/- 5.2 mmHg

134 of vision loss or blindness and reduction of intraocular pressure (IOP) has been proven beneficial in

135 nometry (GAT) error relative to intracameral intraocular pressure (IOP) has not been examined compara

136 t 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model o

137 tics for the treatment of glaucoma, lowering intraocular pressure (IOP) in animal models and cultured

138 y/Phacoviscocanalostomy (VC/PVC) in lowering intraocular pressure (IOP) in Normal Tension Glaucoma (N

139 Prostaglandin analogs reduce intraocular pressure (IOP) in patients with open-angle g

140 ciations between systemic medication use and intraocular pressure (IOP) in the general population.

141 Although effective drugs that lower intraocular pressure (IOP) in the management of glaucoma

142 h a diagnosis of OAG or OHT with unmedicated intraocular pressure (IOP) in the range of 22 to 36 mmHg

143 can estimate the characteristics of 24-hour intraocular pressure (IOP) in treated POAG patients.

144 Postoperative complications were intraocular pressure (IOP) increase (n = 12), cystoid ma

145 Elevated intraocular pressure (IOP) is a major risk factor for gl

146 Intraocular pressure (IOP) is a major risk factor, as we

147 Elevated intraocular pressure (IOP) is a well-known adverse event

148 Accurate determination of intraocular pressure (IOP) is crucial for the diagnosis

149 Intraocular pressure (IOP) is maintained as a result of

150 In the eye, intraocular pressure (IOP) is tightly regulated and its

151 experience disease progression at different intraocular pressure (IOP) levels to aid clinicians with

152 normotensive glaucoma rabbit model for their intraocular pressure (IOP) lowering effects and showed i

153 The mean intraocular pressure (IOP) measured with Goldmann Applan

154 ects also had to be able to obtain the first intraocular pressure (IOP) measurement within 5 mmHg of

155 , and family history; visual acuity testing, intraocular pressure (IOP) measurement, and corneal pach

156 roducibility (inter-operator variability) of intraocular pressure (IOP) measurements with servo-contr

157 libercept group included 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater th

158 is the rate of surgical failure, defined as intraocular pressure (IOP) more than 21 mmHg or reduced

159 traocular surgery or refractory glaucoma and intraocular pressure (IOP) of >/=18 mmHg in whom glaucom

160 of persistent appositional angle closure and intraocular pressure (IOP) of more than 21 mmHg were enr

161 was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes.

162 eated eye as a co-variable for adjustment of intraocular pressure (IOP) outcomes following selective

163 The primary outcome was failure, defined as intraocular pressure (IOP) outside the target range (5-1

164 To investigate whether pre-operative intraocular pressure (IOP) predicts outcome of trabecule

165 ilure, with failure defined as 2 consecutive intraocular pressure (IOP) readings of <6 mmHg with visi

166 The mean intraocular pressure (IOP) recorded at the pre-switch vi

167 Primary outcome measure was intraocular pressure (IOP) reduction.

168 Primary outcome measure was intraocular pressure (IOP) reduction.

169 Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need.

170 The most common adverse event was intraocular pressure (IOP) rise.

171 d 150muL, were suprachoroidally injected and intraocular pressure (IOP) tonometry, fundus photography

172 aucoma has been established by elevating the intraocular pressure (IOP) via microbead occlusion of oc

173 Mean intraocular pressure (IOP) was assessed at 8 AM, 10 AM,

174 s of data, increased fellow eye preoperative intraocular pressure (IOP) was associated with decreased

175 At follow up intraocular pressure (IOP) was measured and adherence to

176 Baseline intraocular pressure (IOP) was measured with a tonometer

177 s administered to 5 normotensive rabbits and intraocular pressure (IOP) was monitored for 28 days.

178 Intraocular pressure (IOP) was monitored.

179 for retinal examination, acute elevation of intraocular pressure (IOP) was observed in the right eye

180 The intraocular pressure (IOP) was significantly higher in t

181 Blood pressure and intraocular pressure (IOP) were measured in the sitting

182 ICP and intraocular pressure (IOP) were simultaneously measured

183 The ability of patients to measure their own intraocular pressure (IOP) would allow more frequent mea

184 disease, whose risk factors include elevated intraocular pressure (IOP), age, and genetics, is charac

185 ilure or last visit, surgical details, final intraocular pressure (IOP), and complications were recor

186 utcome measures included visual acuity (VA), intraocular pressure (IOP), and number of medications.

187 Visual outcomes, slit lamp biomicroscopy, intraocular pressure (IOP), and posterior segment visual

188 CH, central corneal thickness (CCT), average intraocular pressure (IOP), and rates of RNFL loss durin

189 Intraocular pressure (IOP), as assessed by tonopen, was

190 tic model adjusting for age, gender, average intraocular pressure (IOP), central corneal thickness (C

191 erse events included a transient increase of intraocular pressure (IOP), exposure keratitis, subconju

192 ma Index (GI) that incorporated preoperative intraocular pressure (IOP), number of medications and vi

193 ange of best-corrected visual acuity (BCVA), intraocular pressure (IOP), pupillary aperture, glare, c

194 Elevated intraocular pressure (IOP), which causes optic nerve dam

195 e are a positive family history and elevated intraocular pressure (IOP), which is also highly heritab

196 To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegra

197 The purpose of this study was to compare intraocular pressure (IOP)-lowering efficacy and safety

198 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatopr

199 To characterize the 12-month intraocular pressure (IOP)-lowering efficacy of selectiv

200 To evaluate the intraocular pressure (IOP)-lowering performance and safe

201 Accurate prediction of the intraocular pressure (IOP)-lowering response in the fell

202 etic mutation causing glaucoma by increasing intraocular pressure (IOP).

203 ggest that hormone therapy favorably affects intraocular pressure (IOP).

204 l fibrotic agent that can cause elevation of intraocular pressure (IOP).

205 s worldwide, and with its major risk factor, intraocular pressure (IOP).

206 currently relies completely on lowering the intraocular pressure (IOP).

207 r tool for the control of nocturnal elevated intraocular pressure (IOP).

208 early as 7 d following induction of elevated intraocular pressure (IOP).

209 in dark-adapted mouse retinas with elevated intraocular pressure (IOP).

210 r there was a correlation with postoperative intraocular pressure (IOP).

211 with primary open-angle glaucoma and stable intraocular pressure (IOP).

212 o maintain normal aqueous humor drainage and intraocular pressure (IOP).

213 l retinal detachment; (6) hypotony/increased intraocular pressure (IOP); (7) macula pucker/epiretinal

214 Nitric oxide (NO) is able to lower intraocular pressure (IOP); however, its therapeutic eff

215 low structures of the eye result in elevated intraocular pressure (IOP); however, the genes and molec

216 ords and classified into subtypes defined by intraocular pressure (IOP; >/= or <22 mmHg) or visual fi

217 man immunodeficiency virus (HIV) and reduced intraocular pressures (IOP).

218 Postoperative success (intraocular pressure [IOP] < 22 mm Hg +/- glaucoma medic

219 rimary outcome measure was surgical success (intraocular pressure [IOP] </=21 mmHg and reduced >/=20%

220 Prevalence and incidence of hypotony (intraocular pressure [IOP] <5 mm Hg) and low IOP (5 mm H

221 Cumulative failure rates (using an intraocular pressure [IOP] target of 6-18 mm Hg inclusiv

222 8 time points as 2/3(mean arterial pressure-intraocular pressure [IOP]).

223 and place of residence), ocular parameters (intraocular pressure [IOP], axial length and mean ocular

224 (age, sex, central corneal thickness [CCT], intraocular pressure [IOP], refraction, medications), as

225 Prevalent and incident OHT with intraocular pressures (IOPs) of >/=21 mmHg, >/=30 mmHg,

226 Elevated intraocular pressure is a highly heritable risk factor f

227 Treatment to lower intraocular pressure is based on topical drugs, laser th

228 Progression usually stops if the intraocular pressure is lowered by 30-50% from baseline.

229 In early-stage disease, intraocular pressure is raised without visual loss.

230 Complications included elevated intraocular pressure leading to glaucoma; cataracts, inc

231 We demonstrate that high intraocular pressure leads to a rapid increase in endoge

232 Security variables included intraocular pressure, lisamine green and fluorescein ocu

233 Tg-MYOC(Y437H/+)/Sod2(+/-) mice had higher intraocular pressure, lost about 37% of RGCs in the peri

234 ulfonamides reported here showed significant intraocular pressure lowering activity in an animal mode

235 Topical intraocular pressure lowering therapy had to be re-initi

236 variants, we are able to determine that the intraocular pressure-lowering effect of pregabalin is de

237 y from trabeculectomy and toward alternative intraocular pressure-lowering procedures highlights the

238 how preservation of the visual field with an intraocular-pressure-lowering drug in patients with open

239 Visual acuity assessment, intraocular pressure measurement, and fundus examination

240 including the best corrected visual acuity, intraocular pressure measurement, gonioscopy, and visual

241 ected visual acuity, slitlamp biomicroscopy, intraocular pressure measurement, gonioscopy, dilated op

242 uation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examinati

243 al atropine with different concentrations on intraocular pressure measurements and myopia progression

244 mily history of glaucoma, visual acuity, and intraocular pressure measurements using the ICare reboun

245 Intraocular pressure measurements were performed with GA

246 ly, and there was no significant increase in intraocular pressure observed until the 10-year follow-u

247 A mild transient rise in intraocular pressure occurred in 3 out of 8 eyes.

248 raocular surgery or refractory glaucoma with intraocular pressure of >18 mm Hg.

249 aplan-Meier analysis, in which patients have intraocular pressure of 21 mm Hg or lower without antigl

250 Success was defined as a final intraocular pressure of 5 to 21 mm Hg as well as a 20% r

251 produced substantial reductions in baseline intraocular pressure of up to 6 mm Hg that were statisti

252 had improved to 20/60 OD and 20/25 OS, with intraocular pressures of 18 mm Hg OD and 19 mm Hg OS.

253 latest follow-up post surgery, all eyes had intraocular pressures of 22 mm Hg or less with or withou

254 vitreous haze score, and presence of raised intraocular pressure or cataract.

255 ion (OR 1.73, P < .0001), prolonged elevated intraocular pressure (OR 2.96, P = .0003), and additiona

256 49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P =

257 mplex thickness was not associated with sex, intraocular pressure, or diabetes.

258 3%) remained stable with adequate control of intraocular pressure over a mean follow-up period of 33.

259 tically significant reductions from baseline intraocular pressure (P < .001), and was noninferior to

260 487), while no correlation was observed with Intraocular pressure (R = -0.052).

261 d deviation [SD], 30.0+/-19.0%) and elevated intraocular pressure (range, 2.4%-64.0%; mean +/- SD, 27

262 d profound ocular hypotony with unrecordable intraocular pressures, reduced vision and choroidal fold

263 Oxidative stress contributes to both intraocular pressure regulation and glaucomatous neuropa

264 Intraocular pressure-related events may take several mon

265 Intraocular pressure-related parameters obtained with 24

266 Another frequent complication was intraocular pressure rise after injection.

267 , which binds to CACNA2D1 protein and lowers intraocular pressure significantly.

268 The frequency of intraocular pressure spikes of 30 mmHg or more between p

269 The intraocular pressure stabilized in three quarters of the

270 form of glaucoma-include older age, elevated intraocular pressure, sub-Saharan African ethnic origin,

271 d Muller gliosis induced by the elevation of intraocular pressure, suggesting that TRPC channels migh

272 ent including ocular massage and lowering of intraocular pressure, the visual loss remained.

273 esultant transudation of fluid and increased intraocular pressure, thereby leading to secondary glauc

274 es of 22 PAC patients with a history of high intraocular pressure underwent imaging with OCT.

275 on eyes for children up to age 5 years, plus intraocular pressure, visual acuity, and axial length at

276 Age, sex, intraocular pressure, visual field (VF) mean deviation (

277 Mean change from baseline intraocular pressure was +2.6 vs +1.7 mm Hg (P = .52).

278 The intraocular pressure was 15 mm Hg postoperatively, and t

279 Baseline mean intraocular pressure was 19.6 mm Hg (SD 4.6) in 258 pati

280 Mean intraocular pressure was 20 mm Hg (median, 16; range, 15

281 At 24 months, mean reduction in intraocular pressure was 3.8 mm Hg (4.0) in 231 patients

282 spective data suggest that better control of intraocular pressure was achieved in the eyes of patient

283 Intraocular pressure was clinically and statistically si

284 Intraocular pressure was controlled with systematic addi

285 Documentation of intraocular pressure was made in 74.1% of Group A and 75

286 Intraocular pressure was measured at 8 am, 12 pm, and 4

287 Intraocular pressure was measured using Goldmann applana

288 Increased intraocular pressure was more common in the combination

289 The mean intraocular pressure was reduced by 13.0 mm Hg (95% CI,

290 Reduction in intraocular pressure was the most frequent outcome speci

291 No difference in intraocular pressures was detected between Tg-TBK1 mice

292 No definitive changes in visual acuity or intraocular pressure were identified.

293 Visual acuity, central retinal thickness and intraocular pressure were measured monthly.

294 and statistically significant reductions in intraocular pressure were observed in these normotensive

295 Reductions in intraocular pressure were related to increases in BMO-MR

296 In all eyes, intraocular pressures were eventually stabilized within

297 d clinical data, including visual acuity and intraocular pressure, were obtained at enrollment and fr

298 max, Kmin), central corneal thickness (CCT), intraocular pressure with Goldmann applanation tonometer

299 Hg as well as a 20% reduction from baseline intraocular pressure with or without medications.

300 netrates the cornea could effectively reduce intraocular pressure, with minimal systemic or local tox